Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell transfusions.
about
Effect of a restrictive transfusion strategy on transfusion-attributable severe acute complications and costs in the US ICUs: a model simulationClinical evidence of blood transfusion effectivenessBlood management in intensive care medicine: CRIT and ABC--what can we learn?8th Annual Toronto Critical Care Medicine Symposium, 30 October-1 November 2003, Toronto, Ontario, CanadaTreating critical illness: the importance of first doing no harmLeucoreduction of blood components: an effective way to increase blood safety?Clinical effects of reverting from leukoreduced to nonleukoreduced blood in cardiac surgery.Is the current management of severe sepsis and septic shock really evidence based?Transfusion trigger in critically ill patients: has the puzzle been completed?Acute lung injury after blood transfusion in mechanically ventilated patients.Use of blood products in pediatric cardiac surgery.Experimental prestorage filtration removes antibodies and decreases lipids in RBC supernatants mitigating TRALI in vivoRestrictive vs liberal blood transfusion for acute upper gastrointestinal bleeding: rationale and protocol for a cluster randomized feasibility trial.Anemia in critical illness: insights into etiology, consequences, and managementLeukoreduced blood components: Advantages and strategies for its implementation in developing countries.Critical Evaluation of the Lund Concept for Treatment of Severe Traumatic Head Injury, 25 Years after Its IntroductionAnemia and blood transfusion in a surgical intensive care unitTransfusion-transmitted parasitic infections.The effect of age and clinical circumstances on the outcome of red blood cell transfusion in critically ill patients.Effects of transfusion with red cells filtered to remove leucocytes: randomised controlled trial in patients undergoing major surgeryThe association of early transfusion with acute lung injury in patients with severe injury.Decreased sepsis related to indwelling venous access devices coincident with implementation of universal leukoreduction of blood transfusions.Prestorage leukoreduction ameliorates the effects of aging on banked blood.Reducing noninfectious risks of blood transfusion.Identification of lipids that accumulate during the routine storage of prestorage leukoreduced red blood cells and cause acute lung injury.Red blood cell transfusion in the critically ill patient.To filter blood or universal leukoreduction: what is the answer?Red blood cell transfusion in the neurological ICU.Infectious and immunologic consequences of blood transfusionTransfusion trigger: when to transfuse?Transfusion-related acute lung injury (TRALI): a clinical review with emphasis on the critically ill.Differential effects of plasma and red blood cell transfusions on acute lung injury and infection risk following liver transplantationPremedication with acetaminophen or diphenhydramine for transfusion with leucoreduced blood products in children.Red blood cell transfusions and the risk of acute respiratory distress syndrome among the critically ill: a cohort study.Transfusion immunomodulation--the case for leukoreduced and (perhaps) washed transfusions.Transfusion-related acute lung injury: a literature review.Update on transfusion medicine.Red Blood Cell Transfusions Impact Pneumonia Rates After Coronary Artery Bypass Grafting.Pulmonary complications of transfused blood componentsNeutrophils release extracellular DNA traps during storage of red blood cell units
P2860
Q21254582-D290CF84-2130-49A0-BF4B-318650549967Q24650921-F370B99A-DA15-4934-B354-7659800E3FE4Q24805702-407E7CC8-6ECA-4DBC-BA20-12C4FF1A3550Q24806297-02C3E25A-E707-463F-A91F-FCD55E7F7BEDQ24813804-DB1D592C-F703-4ECA-BD80-AF7F40E7A98DQ26771857-FFA09BED-BEA1-474B-878B-56FE26337B35Q33236246-305A10E8-A546-46A1-95C4-1B84009DD484Q33255319-4AF18D8F-19C9-4FA2-A8D0-3D896B17090AQ33344169-5B26A102-FFB8-4759-901D-AE8E7954CD1BQ33362738-682B5134-1E3F-469C-8B6A-7466E300A05FQ33420011-4F914423-557E-456D-8038-271B1A3D4984Q33697274-534319CB-4949-45C5-AC25-FD605828BD0AQ33713993-99326A6F-6C03-4421-A612-316D82BD1E72Q33738712-CF6322E6-5CAD-4790-889F-5D3A56752336Q33760699-F21832AC-C8F0-4FDA-B1ED-35455AC15AABQ33867530-54B31033-6043-4FA5-AE0E-118B800E796CQ34026878-21A06E59-6AC2-4F41-95F7-3820E8353183Q34118802-88679152-77D7-47AE-B582-0007AC6FA2A0Q34241747-77F016AA-6F79-4E0E-89E0-002F8FFA4D11Q34362686-E15BF0A4-3678-4C68-A936-8625DB027D7EQ34433207-CE2BE536-4DEF-4D0F-8997-CA650F4FEE57Q34453403-EB99B115-7280-41B2-BA9F-A1C8F95C654DQ35157783-C1210538-B807-4162-82B4-5A9DCE4FA797Q35182094-EB6C4FE3-5701-42AC-A80F-A5D0E3A3C88FQ35231541-5AC1F5CF-E579-4DCE-9BA2-6574011EA397Q35520728-A649AF09-BA9E-452A-B980-0743B5DCB4A6Q35578991-F92CC68A-3CDB-4D6C-8EE3-05C1E3A6F2DFQ35729682-98EE13C4-21C4-4A4E-AB30-D2AF6BD874D5Q35804510-A9DD192C-642A-45B6-B4C9-E7D80B279447Q35804524-FF41300E-E770-46B7-ADAB-4A42F7F79DC0Q35940036-33E41A4F-C1A5-48CA-BCA2-8474F941C181Q36103363-5F80C94C-D1D6-4AE8-9478-77313F921FE5Q36237664-AC2C0130-DE29-4392-80B4-A9EECD6FDAEBQ36392495-4F28FD25-A74A-417D-AE24-832DB3A4B6A7Q36428284-9BE096D0-C0A6-4D56-8A28-BBCDCA9EF8B4Q36546623-AEA5B699-D3D5-4586-870C-85CA9D6C6B76Q36920718-19F636A2-6535-4321-A852-40DC66AAC649Q36996206-09D57F45-A63D-4444-BAB2-6D2FF69B46F9Q37056509-3B2E35FC-8959-413F-8C32-4937458461D6Q37057078-FEE0E49B-3DF2-4B44-AEAB-5483431337A1
P2860
Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell transfusions.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Clinical outcomes following in ...... r red blood cell transfusions.
@en
type
label
Clinical outcomes following in ...... r red blood cell transfusions.
@en
prefLabel
Clinical outcomes following in ...... r red blood cell transfusions.
@en
P2093
P356
P1476
Clinical outcomes following in ...... or red blood cell transfusions
@en
P2093
Andrew Kmetic
Baldwin Toye
Carl vanWalraven
Dana Devine
George A Wells
Graham D Sher
Irwin Schweitzer
Leukoreduction Study Investigators
Marc Germain
Mindy Goldman
P304
P356
10.1001/JAMA.289.15.1941
P407
P577
2003-04-01T00:00:00Z